Cambridge, UK, 19th June 2021 – TRx is pleased to announce the commencement of an exclusive technology licensing and development partnership with Monument Therapeutics, a neuroscience drug development specialist combining digital biomarkers with therapeutics to provide a precision medicine approach in clinical areas of high unmet need. The completion of this transaction will see TRx technology applied within Monument’s MT1980 neuroinflammation programme in order to solve issues related to poor pharmacokinetics and blood brain barrier penetration, maximally leveraging pharmacology in the brain that would not otherwise be accessible.

TRx CEO, Dr Robin Bannister said “TRx is delighted to have completed its first out-licensing transaction for our novel technology platform. Monument Therapeutics has a unique understanding and approach to neuroscience clinical development and we look forward to closely supporting the team in its plans to uniquely leverage novel neuroinflammatory pharmacology within the brain”.

Under the terms of the agreement TRx will receive a mixture of upfront payments and royalties with the opportunity to broaden the partnership across Monument’s wider future portfolio.